Breast Cancer

**Endocrine Therapy**
- ER/PR-POSITIVE HER2 NEGATIVE
  - CDK 4/6i + PARPi
- HER2 POSITIVE
- "TRIPLE NEGATIVE" EP/PR-NEGATIVE HER2-NEGATIVE

**Pre-Op Therapy**
- No Trial Currently Available

**Surgical Therapy**
- No Trial Currently Available

**Adjuvant Therapy**
- No Trial Currently Available

**1st line MBC Therapy**
- No Trial Currently Available

**2nd line MBC Therapy**
- No Trial Currently Available

**3rd line MBC Therapy**
- No Trial Currently Available

"Heavily Pre-treated" Therapy
- IRB# TBD

**CROSS-DISEASE TRIALS:**
- IRB# TBD EAY131 (MATCH)
- IRB# 18084 S1609 DART

**Key**
- Open for Enrollment
- In Development
- Enrollment on Hold

IRB# 6256 ISPY2 Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2

IRB# 17461 S1418 A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy

IRB# 19358 Elacestrant Monotherapy vs. SOC for Advanced BC following CDK4/6 Inhibitor Therapy

IRB# 19078 S1501: Prospective Evaluation of Carvediolol in Prevention of Cardiac Toxicity in Patients with Metastatic HER2+ BC, Phase III

IRB# 19200 DS-8201a vs. Physician’s Choice for HER2-low Unresectable /Metastatic BC

IRB# 19200 DS-8201a Compared to Treatment of Physician’s Choice for HER2-low Unresectable /Metastatic Breast Cancer

IRB# 19358 Elacestrant Monotherapy vs. SOC for Advanced BC following CDK4/6 Inhibitor Therapy

IRB# 19830 T-DM1 and Palbociclib in Metastatic HER2+ BC

IRB# 20112 T-DM1 and Tucatinib/Placebo in Metastatic HER2+ BC

IRB# 18504 Phase 2 Olaparib and Durvalumab in Patients with Metastatic Triple Negative Breast Cancer

IRB# TBD EAY131 (MATCH)

IRB# 18084 S1609 DART

http://www.ohsu.edu/research/rda/so/knight.php